• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TeraDiscoveries, Egenix partner for cancer, autism drugs

TeraDiscoveries, Egenix partner for cancer, autism drugs

February 26, 2014
CenterWatch Staff

TeraDiscoveries has formed a strategic partnership with Egenix, a privately held New York-based biotechnology firm. The two companies are working together to design new drugs to treat cancer and autism.  

TeraDiscoveries will use its Inverse Design software platform to design new drug molecules to effectively help Egenix accelerate its drug discovery and development process. Egenix is providing funding and target data that TeraDiscoveries will apply to identify and optimize inhibitors for certain cancer indications and autism. Egenix will develop the drugs through phase II, while TeraDiscoveries retains a minority stake in the two drugs.

Inverse Design runs computational models to quickly scan a vast chemical space to find the strongest inhibitors of a specific biological target, ones that also have good druggable properties and are predicted to have low toxic side effects. Inverse Design also has filters for many important drug properties including toxic side-effect risk assessment, off-target effects assessment, synthesizability, solubility and freedom to operate assessment. Specialized filtering can assess if a molecule crosses the blood-brain barrier.

Companies can use Inverse Design as a service and run it via the Windows Azure cloud or a private cloud to design, discover or optimize new small molecule or peptide drugs for their targets. TeraDiscoveries also partners and licenses assets in its pipeline which include compounds for many targets including Jak2, Jak3, hdac8, Aurora A, 11b-HSD1, hsp90, MAPK10, pfDHFR-Ts, ABL1, ABL3, ROCK1, TYK2 and c-Kit.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing